For the Inventor, By the Inventor

Enter assignee name

Plymouth Meeting, PA, United States of America

Inovio Pharmaceuticals, Inc.

USPTO Granted Patents = 87

CIPO Patents = 15

EPO Patents = 40

Trademarks = 6

Forward Citations = 49

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

David B Weiner (53 out of 185 patents)

Jian Yan (44 out of 69 patents)

Niranjan Y Sardesai (23 out of 30 patents)

4. Kate Broderick (15 out of 19 patents)

5. Karuppiah Muthumani (14 out of 30 patents)

6. Stephen V Kemmerrer (14 out of 18 patents)

7. Anna Slager (11 out of 11 patents)

8. Neil Cooch (10 out of 10 patents)

9. Bernadette Ferraro (10 out of 12 patents)

10. Jay R McCoy (10 out of 29 patents)

11. Bradley Garman (9 out of 9 patents)

12. Matthew P Morrow (8 out of 23 patents)

13. Mathura P Ramanathan (8 out of 14 patents)

14. Ruxandra Draghia-Akli (5 out of 28 patents)

15. Kar Muthumani (4 out of 11 patents)

Core Competencies:

Cancer Vaccines

Electroporation Device

Nucleic Acid Constructs

Immunotherapy

Synthetic Immunogens

Intradermal Injection

Virus Vaccines

Adjuvants

Minimally Invasive Techniques

Antibody Constructs

Filovirus Antigens

Checkpoint Inhibitors

87 patents: Sort by Forward Citations

1. 12491361 - Tolerable and minimally invasive skin electroporation device (2025-12-09),

2. 12350318 - Combination therapy to treat brain cancer (2025-07-08),

3. 12285473 - Cancer vaccines targeting MUC16 and uses thereof (2025-04-29),

4. 12280108 - Vaccines having an antigen and interleukin-21 as an adjuvant (2025-04-21),

5. 12251561 - Minimally invasive dermal electroporation device (2025-03-18),

6. 12240872 - Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same (2025-03-04),

7. 12161706 - Cancer vaccines targeting BORIS and uses thereof (2024-12-10),

8. 12128229 - Oral mucosal electroporation device and use thereof (2024-10-29),

9. 12109258 - Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections (2024-10-08),

10. D1041653 - Cap for a hand-held electroporation device (2024-09-10),

11. 12064473 - Cancer vaccines targeting Survivin and uses thereof (2024-08-20),

12. 12054537 - Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies (2024-08-06),

13. 12053619 - Intradermal jet injection electroporation (2024-08-06),

14. 12049479 - Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom (2024-07-30),

15. 11986517 - Cancer vaccines targeting mesothelin and uses thereof (2024-05-21),

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA-based immunotherapies for the treatment of cancer and infectious diseases. With a proprietary DNA medicine platform, Inovio aims to transform the way diseases are prevented and treated. The company's innovative approach utilizes synthetic DNA plasmids delivered directly into cells using electroporation, triggering an immune response to target and eliminate specific diseases. Inovio's diverse pipeline includes potential treatments for cervical dysplasia, prostate cancer, HIV, hepatitis B, and other challenging diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

87 Patents

#2 in Plymouth Meeting, PA

#158 in Pennsylvania

#4,141 in US

#8,539 in the World

Plymouth Meeting, PA, United States of America

Inovio Pharmaceuticals, Inc.

Forward Citations = 49

70 inventors:

David B Weiner (53 out of 185 patents)

Jian Yan (44 out of 69 patents)

Niranjan Y Sardesai (23 out of 30 patents)

4. Kate Broderick (15 out of 19 patents)

5. Karuppiah Muthumani (14 out of 30 patents)

Please report any incorrect information to support@idiyas.com

Loading…